Medullary thyroid cancer in MEN2 pediatric/adolescent carriers of RET mutation: genotype/phenotype correlation and outcome in a retrospective series of 23 patients

被引:0
|
作者
Di Benedetto, Guenda [1 ]
Barca, Ignazio [1 ]
De Gregorio, Laura [2 ]
Scollo, Claudia [3 ]
Giani, Fiorenza [1 ]
Martorana, Federica [4 ]
Russo, Marco [1 ]
Frasca, Francesco [1 ]
Pellegriti, Gabriella [1 ,4 ]
Sapuppo, Giulia [1 ]
机构
[1] Univ Catania, Garibaldi Nesima Hosp, Dept Clin & Expt Med, Endocrinol Unit, Catania, Italy
[2] Multidiagnost Hlth Serv Ctr, Mol Biol Serv, Catania, Italy
[3] Maggiore Hosp, Dept Internal Med, Endocrinol Serv, Modica, Italy
[4] Univ Catania, Dept Clin & Expt Med, Med Oncol, Catania, Italy
来源
FRONTIERS IN ONCOLOGY | 2025年 / 14卷
关键词
pediatric and adolescent MEN 2; childhood medullary thyroid cancer; RET mutation; response to treatment; outcome; persistent disease; thyroid cancer; PROPHYLACTIC THYROIDECTOMY; CARCINOMA; GUIDELINES; MANAGEMENT; PAPILLARY;
D O I
10.3389/fonc.2024.1464890
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Multiple endocrine neoplasia type 2 syndrome (MEN2) is a hereditary disease resulting from mutations of the rearranged during transfection (RET) protooncogene subclassified into MEN2A [medullary thyroid carcinoma (MTC), pheochromocytoma, and primary hyperparathyroidism] and MEN2B (MTC, pheochromocytoma, Marfanoid habitus, mucous neuromas, and intestinal ganglioneuromatosis). Prophylactic thyroidectomy is recommended in RET-mutated patients. The age at which it should be performed depends on the type and aggressiveness of the mutation.Aim of the study This study aimed to evaluate the genotype/phenotype correlation and outcome in pediatric/adolescent carriers of MEN2 RET mutation.Patients and methods In a retrospective series of 23 carriers of RET MEN2 mutation who were <= 19 years old at diagnosis and had undergone total thyroidectomy +/- lymphadenectomy, the following were analyzed: 1) specific RET mutation, 2) clinical and histopathological characteristics, 3) genotype/phenotype correlation, and 4) outcome at last follow-up.Results In our series, the female gender was more prevalent (F/M ratio 2.8/1), and the median age was 14.9 years [interquartile range (IQR) 12.6-17.2]. RET mutations were at very high risk in 4.3% of patients (M918T), high risk in 43.5% (C634), and moderate risk in 52.2% (47.8% C618 and 4.3% C620). All patients underwent surgery: at histology, MTC was found in 19/23 (82.6%) patients, C-cell hyperplasia in 2/23 (8.7%), and benign histology in 2/23 (8.7%). Ten patients (52.6%) had a disease event during the follow-up: 2/19 (10.5%) showed biochemical disease, 6/19 (31.6%) lymph node recurrences, and 2/19 (10.5%) distant metastases (50% liver, 50% bone). At the last follow-up, nine MTCs were not cured. One patient died after 9 years of follow-up at 21 years old (M918T RET+).Conclusions From these data, it is clear to see the importance of genetic counseling and RET screening in all first-degree relatives of patients with proven MEN2. The goal should be to subject patients to surgery for prophylactic and not curative purposes, i.e., before the onset of MTC, given the high risk of persistent or recurrent disease also in pediatric/adolescent patients.
引用
收藏
页数:8
相关论文
共 18 条
  • [1] Genotype and phenotype landscape of MEN2 in 554 medullary thyroid cancer patients: the BrasMEN study
    Maciel, Rui M. B.
    Camacho, Cleber P.
    Assumpcao, Ligia V. M.
    Bufalo, Natassia E.
    Carvalho, Andre L.
    de Carvalho, Gisah A.
    Castroneves, Luciana A.
    de Castro Jr, Francisco M.
    Ceolin, Lucieli
    Cerutti, Janete M.
    Corbo, Rossana
    Ferraz, Tania M. B. L.
    Ferreira, Carla, V
    Franca, M. Inez C.
    Galvao, Henrique C. R.
    Germano-Neto, Fausto
    Graf, Hans
    Jorges, Alexander A. L.
    Kunii, Ilda S.
    Lauria, Marcio W.
    Leal, Vera L. G.
    Lindsey, Susan C.
    Lourenco Jr, Delmar M.
    Mader, Lea M. Z.
    Magalhaes, Patricia K. R.
    Martins, Joao R. M.
    Cecilia Martins-Costa, M.
    Mazetor, Glaucia M. F. S.
    Impellizzeri, Anelise I.
    Nogueira, Celia R.
    Palmero, Edenir, I
    Pessoa, Cencita H. C. N.
    Prada, Bibiana
    Siqueira, Debora R.
    Sousa, Maria Sharmila A.
    Toledo, Rodrigo A.
    Valente, Flavia O. F.
    Vaisman, Fernanda
    Ward, Laura S.
    Weber, Shana S.
    Weiss, Rita, V
    Yang, Ji H.
    Dias-da-Silva, Magnus R.
    Hoff, Ana O.
    Toledo, Sergio P. A.
    Maia, Ana L.
    ENDOCRINE CONNECTIONS, 2019, 8 (03): : 289 - 298
  • [2] RET mutation screening in MEN2 patients and discovery of a novel mutation in a sporadic medullary thyroid carcinoma
    Jhiang, SM
    Fithian, L
    Weghorst, CM
    Clark, OH
    Falko, JM
    ODorisio, TM
    Mazzaferri, EL
    THYROID, 1996, 6 (02) : 115 - 121
  • [3] RET Genotype & MEN2 Phenotype correlation in a large Indian Medullary Thyroid Carcinoma (MTC) cohort & influence of SNPs in 3 genetic pathways on MTC behavior
    Mishra, V.
    Kowtal, P.
    Reddy, R.
    Mahida, N.
    Sarin, R.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 447 - 448
  • [4] Pheochromocytoma and medullary thyroid carcinoma:: A new genotype-phenotype correlation of the RET protooncogene 891 germline mutation
    Jimenez, C
    Habra, MA
    Huang, SCE
    El-Naggar, A
    Shapiro, SE
    Evans, DB
    Cote, G
    Gagel, RF
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (08): : 4142 - 4145
  • [5] Pheochromocytoma and medullary thyroid carcinoma: a new genotype-phenotype correlation of the RET protooncogene 891 germline mutation
    Jimenez, C
    Habra, MA
    Huang, SC
    Cote, GJ
    Evans, DB
    Shapiro, SE
    El-Naggar, A
    Gagel, RF
    JOURNAL OF INTERNAL MEDICINE, 2004, 255 (06) : 712 - 712
  • [6] Familial medullary thyroid carcinoma with noncysteine RET mutations: Phenotype-genotype relationship in a large series of patients
    Niccoli-Sire, P
    Murat, A
    Rohmer, V
    Franc, S
    Chabrier, G
    Baldet, L
    Maes, B
    Savagner, F
    Giraud, S
    Bezieau, S
    Kottler, ML
    Morange, S
    Conte-Devolx, B
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (08): : 3746 - 3753
  • [7] A DHPLC protocol for detecting RET proto-oncogene mutations in MEN2 patients and medullary thyroid carcinoma.
    Torrente, I
    De Luca, A
    Conte, C
    Mangino, M
    Chiefari, E
    Arturi, F
    Filetti, S
    Novelli, G
    Dallapiccola, B
    AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 69 (04) : 442 - 442
  • [8] Thyroid Malignancy and Cutaneous Lichen Amyloidosis: Key Points Amid RET Pathogenic Variants in Medullary Thyroid Cancer/Multiple Endocrine Neoplasia Type 2 (MEN2)
    Stanescu, Laura-Semonia
    Ghemigian, Adina
    Ciobica, Mihai-Lucian
    Nistor, Claudiu
    Ciuche, Adrian
    Radu, Andreea-Maria
    Sandru, Florica
    Carsote, Mara
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (18)
  • [9] Penetrance of inherited medullary thyroid carcinoma and genotype-phenotype correlation in a large multiple endocrine neoplasia type 2A family with C634Y RET mutation
    González-Yebra, B
    Medrano, ME
    Mantilla, A
    Palma, V
    Colin, C
    Hernández, DM
    Tapia, J
    Dawson, B
    Salcedo, M
    ENDOCRINE PATHOLOGY, 2003, 14 (01) : 71 - 80
  • [10] Evaluation of the role of RET polymorphisms/haplotypes as modifier loci for MEN 2, and analysis of the correlation with the type of RET mutation in a series of Spanish patients
    Fernández, RM
    Navarro, E
    Antiñolo, G
    Ruiz-Ferrer, M
    Borrego, S
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2006, 17 (04) : 575 - 581